TCRX Stock Overview
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.
TScan Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.10|
|52 Week High||US$14.71|
|52 Week Low||US$1.60|
|1 Month Change||-1.90%|
|3 Month Change||10.71%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-70.48%|
Recent News & Updates
Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
|TCRX||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how TCRX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how TCRX performed against the US Market.
|TCRX Average Weekly Movement||15.8%|
|Biotechs Industry Average Movement||13.1%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: TCRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: TCRX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.
TScan Therapeutics Fundamentals Summary
|TCRX fundamental statistics|
Is TCRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TCRX income statement (TTM)|
|Cost of Revenue||US$52.31m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.38|
|Net Profit Margin||-510.72%|
How did TCRX perform over the long term?See historical performance and comparison
Is TCRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TCRX?
Other financial metrics that can be useful for relative valuation.
|What is TCRX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does TCRX's PS Ratio compare to its peers?
|TCRX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
VTVT vTv Therapeutics
PTN Palatin Technologies
BOLT Bolt Biotherapeutics
LVTX LAVA Therapeutics
TCRX TScan Therapeutics
Price-To-Sales vs Peers: TCRX is good value based on its Price-To-Sales Ratio (6.7x) compared to the peer average (33.8x).
Price to Earnings Ratio vs Industry
How does TCRX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: TCRX is good value based on its Price-To-Sales Ratio (6.7x) compared to the US Biotechs industry average (13.4x)
Price to Sales Ratio vs Fair Ratio
What is TCRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||6.7x|
|Fair PS Ratio||0.03x|
Price-To-Sales vs Fair Ratio: TCRX is expensive based on its Price-To-Sales Ratio (6.7x) compared to the estimated Fair Price-To-Sales Ratio (0x).
Share Price vs Fair Value
What is the Fair Price of TCRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate TCRX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TCRX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TCRX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is TScan Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TCRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TCRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TCRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TCRX's revenue is expected to decline over the next 3 years (-0.3% per year).
High Growth Revenue: TCRX's revenue is forecast to decline over the next 3 years (-0.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TCRX is forecast to be unprofitable in 3 years.
Discover growth companies
How has TScan Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: TCRX is currently unprofitable.
Growing Profit Margin: TCRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TCRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TCRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: TCRX has a negative Return on Equity (-39.03%), as it is currently unprofitable.
Discover strong past performing companies
How is TScan Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: TCRX's short term assets ($145.7M) exceed its short term liabilities ($18.5M).
Long Term Liabilities: TCRX's short term assets ($145.7M) exceed its long term liabilities ($4.0M).
Debt to Equity History and Analysis
Debt Level: TCRX is debt free.
Reducing Debt: TCRX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TCRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TCRX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 74.9% each year.
Discover healthy companies
What is TScan Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TCRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TCRX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TCRX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Southwell (60 yo)
Mr. David P. Southwell has been a Director of PTC Therapeutics, Inc. since December 19, 2005. He serves as Chief Executive Officer, President and Director of TScan Therapeutics, Inc. since October 2018. Mr...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD2.79M) is above average for companies of similar size in the US market ($USD759.63K).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
Experienced Management: TCRX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: TCRX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TCRX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: TCRX only recently listed within the past 12 months.
TScan Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: TScan Therapeutics, Inc.
- Ticker: TCRX
- Exchange: NasdaqGM
- Founded: 2018
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$74.225m
- Shares outstanding: 23.94m
- Website: https://www.tscan.com
Number of Employees
- TScan Therapeutics, Inc.
- 830 Winter Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/29 00:00|
|End of Day Share Price||2022/06/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.